Despite over $34B spent annually on CNS drug development, over 90% of candidates fail—primarily due to outdated models that can’t replicate the critical first trimester of human brain development. Animal models and traditional organoids miss region-specific and vascular interactions essential to understanding complex disorders like autism and epilepsy.
The company has developed the first AI-powered, multi-region brain organoid (MRBO) system that integrates cerebral, midbrain, hindbrain, and vascular elements. This next-gen human model captures early neural development with unmatched biological accuracy. Backed by Johns Hopkins, peer-reviewed data, and early commercial pilots (including $160K+ in contracted studies), the platform is validated for both scientific and market credibility.
With NIH and FDA policy shifts accelerating the move toward human-relevant models, the timing is ideal. The company stands alone in enabling vascularized modeling of early-stage brain function, creating a defensible lead in a $56B total addressable market. A 25x scale-up plan is underway to support pharma, biotech, and diagnostics clients, with expansion into proprietary CNS drug discovery on the roadmap.
Raising $1.75M to automate production (500 organoids/day), expand certification pilots, and secure IP, the company is positioned to become the gold standard in brain health validation. Strategic alignment with pharma and healthtech leaders supports a clear path to acquisition, with potential buyers including pharma giants and digital biomarker platforms.
View the deck through the link below. Some unique identifiers have been removed. For access to detailed materials, please reach to us or your point of contact, as full decks are only shared upon request to maintain confidentiality and exclusivity.
View Pitch Deck